低体积淋巴结T1-2头颈癌:放疗alone与同步放化疗的多中心队列生存比较
该多中心队列纳入240例AJCC第7版T1-2N1-2a头颈鳞癌患者,采用IPTW平衡基线后比较根治性放疗与同步放化疗(CCRT)。CCRT未显著改善总生存(HR 0.50,95%CI 0.20-1.24,P=0.14),但显著改善无进展生存(HR 0.42,95%CI 0.19-0.93,P=0.03)。
要点
- CCRT未显著改善OS,但显著改善PFS。
- 需权衡生存获益与治疗相关毒性。
- 结论需更大前瞻性研究验证。
核心结论
- 在T1-2N1-2a头颈鳞癌患者中,CCRT对OS获益有限,但可改善部分患者的肿瘤进展控制。
研究设计与样本
- 多中心队列研究,纳入240例AJCC第7版T1-2N1-2a头颈鳞癌患者,中位年龄57.8岁(IQR 52.0-65.1),51例(21%)HPV阴性。
- 采用逆概率治疗加权(IPTW)平衡基线差异,用Kaplan-Meier分析和Cox比例风险模型比较OS和PFS。
主要发现
- IPTW调整后多因素Cox分析显示,CCRT相比单纯放疗未显著改善OS(HR 0.50;95%CI 0.20-1.24;P=0.14)。
- CCRT与PFS显著改善相关(HR 0.42;95%CI 0.19-0.93;P=0.03)。
- 与NRG-HN002试验一致,CCRT相对单纯放疗使局部区域失败绝对减少9.7%。
关键数值与推荐
- OS的HR为0.50(95%CI 0.20-1.24;P=0.14)。
- PFS的HR为0.42(95%CI 0.19-0.93;P=0.03)。
- CCRT相对单纯放疗局部区域失败绝对减少9.7%。
临床怎么用
- 对T1-2N1-2a低体积淋巴结头颈鳞癌,选择CCRT前应仔细评估生存获益与治疗相关毒性。
局限性
- 需要更大规模的前瞻性研究来验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal treatment strategy between definitive radiotherapy and concurrent chemoradiotherapy (CCRT) for patients with T1-2 head and neck cancer with low-volume nodal disease remains unclear due to limited supporting data. This study aimed to compare overall survival (OS) and progression-free survival (PFS) between the two treatment modalities. METHODS: Patients with AJCC 7th edition stage T1-2N1-2a head and neck squamous cell carcinoma (HNSCC) were collected from multiple research centers, including the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (NCC), the University Health Network (UHN), and Quebec, Canada. Inverse probability of treatment weighting (IPTW) was applied to balance baseline differences. Kaplan-Meier analysis and Cox proportional hazards models were used to compare OS and PFS between the two groups. RESULTS: A total of 240 patients were included, with a median age of 57.8 years (IQR 52.0-65.1); 51 patients (21%) were HPV-negative. After IPTW adjustment, multivariable Cox analysis showed that CCRT did not provide a significant OS benefit compared with radiotherapy alone (hazard ratio [HR], 0.50; 95% CI, 0.20-1.24; P = 0.14). However, CCRT was associated with a significant improvement in PFS (HR, 0.42; 95% CI, 0.19-0.93; P = 0.03). Consistent with the NRG-HN002 trial, which showed a 9.7% absolute reduction in locoregional failure with CCRT relative to radiotherapy alone. CONCLUSIONS: This multicenter study demonstrated that while CCRT conferred limited OS benefit in patients with stage T1-2N1-2a HNSCC, it improved tumor progression control in a subset of patients. Careful evaluation of survival benefit versus treatment-related toxicity is warranted, and larger prospective studies are needed to validate these findings.
引用
- Zhang C, Cheng Z, Jiang X, et al. Survival outcomes of radiotherapy alone versus concurrent chemoradiotherapy in T1-2 head and neck cancer with low-volume disease: A multicenter cohort study. Clin Transl Radiat Oncol. 2026. PMID: 42440420. doi:10.1016/j.ctro.2026.101223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。